"Intravitreal Injections" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The administration of substances into the VITREOUS BODY of the eye with a hypodermic syringe.
Descriptor ID |
D058449
|
MeSH Number(s) |
E02.319.267.530.475.500
|
Concept/Terms |
Intravitreal Injections- Intravitreal Injections
- Injection, Intravitreal
- Injections, Intravitreal
- Intravitreal Injection
|
Below are MeSH descriptors whose meaning is more general than "Intravitreal Injections".
Below are MeSH descriptors whose meaning is more specific than "Intravitreal Injections".
This graph shows the total number of publications written about "Intravitreal Injections" by people in this website by year, and whether "Intravitreal Injections" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2010 | 1 | 1 | 2 |
2011 | 0 | 1 | 1 |
2012 | 0 | 4 | 4 |
2013 | 0 | 3 | 3 |
2014 | 0 | 3 | 3 |
2015 | 0 | 2 | 2 |
2016 | 0 | 6 | 6 |
2017 | 0 | 7 | 7 |
2018 | 0 | 4 | 4 |
2019 | 1 | 4 | 5 |
2020 | 0 | 4 | 4 |
2021 | 0 | 1 | 1 |
2022 | 0 | 3 | 3 |
2023 | 0 | 4 | 4 |
2024 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Intravitreal Injections" by people in Profiles.
-
Intravitreal Metformin Protects Against Choroidal Neovascularization and Light-Induced Retinal Degeneration. Int J Mol Sci. 2024 Oct 22; 25(21).
-
Bevacizumab for Retinopathy of Prematurity Is Not Associated With Systemic Hypertension. J Pediatr Ophthalmol Strabismus. 2024 Nov-Dec; 61(6):434-441.
-
Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 Aug 01; 142(8):716-721.
-
Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration. Sci Rep. 2024 06 26; 14(1):14752.
-
Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials. Ophthalmol Retina. 2024 Nov; 8(11):1052-1060.
-
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023 Dec 01; 141(12):1152-1160.
-
Association of Health Insurance Status With Severity and Treatment Among Infants With Retinopathy of Prematurity. J Pediatr Ophthalmol Strabismus. 2023 Nov-Dec; 60(6):e75-e78.
-
Review on the Safety and Efficacy of Brolucizumab for Neovascular Age-Related Macular Degeneration From Major Studies and Real-World Data. Asia Pac J Ophthalmol (Phila). 2023 Mar-Apr 01; 12(2):168-183.
-
The 0.19-mg Fluocinolone Acetonide Implant for the Treatment of Diabetic Macular Edema: An Expert Consensus. Ophthalmic Surg Lasers Imaging Retina. 2023 03; 54(3):166-173.
-
Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis. BMJ Open Ophthalmol. 2022; 7(1):e000957.